The European Society for Medical Oncology (ESMO) Annual Meeting, showcased an array of updates in breast cancer care and management, including updates on pivotal trials in the early and metastatic breast cancer settings.

In this podcast, we hear from leading experts, Elisa Agostinetto and Evandro de Azambuja (Jules Bordet, Brussels, Belgium) who discuss the latest advances in breast cancer from ESMO 2022. In hormone receptor-positive HER2-negative breast cancer, overall survival results from the TROPiCS-02 study (NCT03901339) evaluating sacituzumab govetican, and MONARCH-3 (NCT02246621) investigating the addition of abemaciclib is discussed. In addition, findings from the DATA trial (NCT00301457), which evaluated whether extended adjuvant endocrine therapy was associated with significant benefit is discussed. In triple-negative breast cancer, the findings from SYNERGY (NCT03616886) and BELLINI (NCT03815890) trials are also considered, which aim to improve understanding of the role of immunotherapy in breast cancer.

This discussion took place at the European Society for Medical Oncology (ESMO) 2022 Annual Meeting, in Paris, France.